Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Laekna, Inc. ( (HK:2105) ).
Laekna, Inc. has called its annual general meeting for 5 June 2026 in Shanghai to seek shareholder approval of its 2025 audited financial statements and the re-election of two executive directors and one independent non-executive director. The company will also request authorization for the board to set director and auditor remuneration and to reappoint KPMG as auditor.
In addition, the board is asking shareholders to grant a general mandate allowing directors to issue, allot, or deal with additional shares and related securities, up to 20% of the company’s issued share capital, excluding treasury shares. If approved, this mandate would give Laekna increased flexibility to raise capital and manage its equity structure, potentially supporting future growth initiatives and strategic financing activities.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange. Operating in the biopharmaceutical sector, it focuses on developing and commercializing innovative therapies, with its corporate presence and shareholder base centered in mainland China and Hong Kong capital markets.
Average Trading Volume: 2,661,812
Technical Sentiment Signal: Hold
Current Market Cap: HK$5.82B
For an in-depth examination of 2105 stock, go to TipRanks’ Overview page.